Review



primary polyclonal human anti-spp1 antibody  (Spring Bioscience)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Spring Bioscience primary polyclonal human anti-spp1 antibody
    ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of <t> SPP1. </t>
    Primary Polyclonal Human Anti Spp1 Antibody, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary polyclonal human anti-spp1 antibody/product/Spring Bioscience
    Average 90 stars, based on 1 article reviews
    primary polyclonal human anti-spp1 antibody - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis"

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    Journal: Cancers

    doi: 10.3390/cancers15235704

    ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of SPP1.
    Figure Legend Snippet: ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of SPP1.

    Techniques Used: Expressing, Staining

    Expression pattern of SPP1 in pan-cancer. ( A ) The expression of the SPP1 mRNA level in multiple TCGA cancers and matching normal tissues. p < 0.001, except Thym cancer ( p = 0.7) and KICH cancer ( p = 0.53). ( B ) Increased mRNA expression level of SPP1 in bladder cancer. ( C ) Promoter methylation status of SPP1 in bladder cancer and matching normal tissues. All data were analyzed using the UALCAN web tool.
    Figure Legend Snippet: Expression pattern of SPP1 in pan-cancer. ( A ) The expression of the SPP1 mRNA level in multiple TCGA cancers and matching normal tissues. p < 0.001, except Thym cancer ( p = 0.7) and KICH cancer ( p = 0.53). ( B ) Increased mRNA expression level of SPP1 in bladder cancer. ( C ) Promoter methylation status of SPP1 in bladder cancer and matching normal tissues. All data were analyzed using the UALCAN web tool.

    Techniques Used: Expressing, Methylation

    Molecular alterations of SPP1 in cancers. ( A ) High amplifications/mutations of the SPP1 gene in bladder cancer compared other cancer types. ( B ) Positions and mutation frequency in SPP1 in bladder cancer.
    Figure Legend Snippet: Molecular alterations of SPP1 in cancers. ( A ) High amplifications/mutations of the SPP1 gene in bladder cancer compared other cancer types. ( B ) Positions and mutation frequency in SPP1 in bladder cancer.

    Techniques Used: Mutagenesis

    Cytoplasmic expression of SPP1 in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( A , B ), weak ( C , D ), moderate ( E , F ) and strong expression ( G , H ) of SPP1. Images were taken using 10× and 40× magnification objectives (scale bar equals 1 mm).
    Figure Legend Snippet: Cytoplasmic expression of SPP1 in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( A , B ), weak ( C , D ), moderate ( E , F ) and strong expression ( G , H ) of SPP1. Images were taken using 10× and 40× magnification objectives (scale bar equals 1 mm).

    Techniques Used: Expressing, Immunohistochemical staining, Staining, Microarray

    Nuclear SPP1 expression in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( C , D ), and strong expression of SPP1 ( A , B ). Images were taken with 10× and 40× magnification objectives (scale bar equals 1 mm).
    Figure Legend Snippet: Nuclear SPP1 expression in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( C , D ), and strong expression of SPP1 ( A , B ). Images were taken with 10× and 40× magnification objectives (scale bar equals 1 mm).

    Techniques Used: Expressing, Immunohistochemical staining, Staining, Microarray

    Correlation between cytoplasmic SPP1 expression and patients’ clinicopathological characteristics.
    Figure Legend Snippet: Correlation between cytoplasmic SPP1 expression and patients’ clinicopathological characteristics.

    Techniques Used: Expressing

    SPP1 expression and patients’ survival. Kaplan–Meier survival curve for bladder cancer patients expressing cytoplasmic ( A ) and nuclear ( B ) patterns of SPP1 (low expression vs. high expression). Low SPP1 immunostaining is associated with poor overall survival (log-rank p = 0.022).
    Figure Legend Snippet: SPP1 expression and patients’ survival. Kaplan–Meier survival curve for bladder cancer patients expressing cytoplasmic ( A ) and nuclear ( B ) patterns of SPP1 (low expression vs. high expression). Low SPP1 immunostaining is associated with poor overall survival (log-rank p = 0.022).

    Techniques Used: Expressing, Immunostaining

    Enrichment analysis of SPP1 in bladder cancer. ( A ) Identification of SPP1-interacting genes. Protein–protein interaction map and hub genes of SPP1. The size of the hub is proportional to the expression level. ( B ) Identification of the SPP1 co-expression network. The figure was generated using the online cBioPortal database. ( C ) KEGG functional enrichment analysis of SPP1. The figure was generated using the online cBioPortal database.
    Figure Legend Snippet: Enrichment analysis of SPP1 in bladder cancer. ( A ) Identification of SPP1-interacting genes. Protein–protein interaction map and hub genes of SPP1. The size of the hub is proportional to the expression level. ( B ) Identification of the SPP1 co-expression network. The figure was generated using the online cBioPortal database. ( C ) KEGG functional enrichment analysis of SPP1. The figure was generated using the online cBioPortal database.

    Techniques Used: Expressing, Generated, Functional Assay

    Correlation between immune cells and SPP1 expression. TIMER analysis of the correlation between SPP1 expression and immune cells’ infiltration. Purity-adjusted Spearman’s rho across various cell types by different algorithms.
    Figure Legend Snippet: Correlation between immune cells and SPP1 expression. TIMER analysis of the correlation between SPP1 expression and immune cells’ infiltration. Purity-adjusted Spearman’s rho across various cell types by different algorithms.

    Techniques Used: Expressing

    Relationship between SPP1 expression and immune checkpoint genes in bladder cancer. ( A ) Correlation analysis between SPP1 expression and immune checkpoint genes. ( B ) The expression of immune checkpoint genes in relation to SPP1 expression. Data were analyzed using the cBioPortal cancer genomics website on TCGA data. The p -value significance codes: *** ≤0.001, ** ≤0.01, * ≤0.05.
    Figure Legend Snippet: Relationship between SPP1 expression and immune checkpoint genes in bladder cancer. ( A ) Correlation analysis between SPP1 expression and immune checkpoint genes. ( B ) The expression of immune checkpoint genes in relation to SPP1 expression. Data were analyzed using the cBioPortal cancer genomics website on TCGA data. The p -value significance codes: *** ≤0.001, ** ≤0.01, * ≤0.05.

    Techniques Used: Expressing



    Similar Products

    primary polyclonal human anti-spp1 antibody  (Spring Bioscience)
    90
    Spring Bioscience primary polyclonal human anti-spp1 antibody
    ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of <t> SPP1. </t>
    Primary Polyclonal Human Anti Spp1 Antibody, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary polyclonal human anti-spp1 antibody/product/Spring Bioscience
    Average 90 stars, based on 1 article reviews
    primary polyclonal human anti-spp1 antibody - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of SPP1.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: ( a ): Baseline clinical and pathological characteristics of bladder cancer patients. ( b ): Median and IQR of patients’ age and follow-up duration. ( c ): Expression intensity of SPP1.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Staining

    Expression pattern of SPP1 in pan-cancer. ( A ) The expression of the SPP1 mRNA level in multiple TCGA cancers and matching normal tissues. p < 0.001, except Thym cancer ( p = 0.7) and KICH cancer ( p = 0.53). ( B ) Increased mRNA expression level of SPP1 in bladder cancer. ( C ) Promoter methylation status of SPP1 in bladder cancer and matching normal tissues. All data were analyzed using the UALCAN web tool.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Expression pattern of SPP1 in pan-cancer. ( A ) The expression of the SPP1 mRNA level in multiple TCGA cancers and matching normal tissues. p < 0.001, except Thym cancer ( p = 0.7) and KICH cancer ( p = 0.53). ( B ) Increased mRNA expression level of SPP1 in bladder cancer. ( C ) Promoter methylation status of SPP1 in bladder cancer and matching normal tissues. All data were analyzed using the UALCAN web tool.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Methylation

    Molecular alterations of SPP1 in cancers. ( A ) High amplifications/mutations of the SPP1 gene in bladder cancer compared other cancer types. ( B ) Positions and mutation frequency in SPP1 in bladder cancer.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Molecular alterations of SPP1 in cancers. ( A ) High amplifications/mutations of the SPP1 gene in bladder cancer compared other cancer types. ( B ) Positions and mutation frequency in SPP1 in bladder cancer.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Mutagenesis

    Cytoplasmic expression of SPP1 in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( A , B ), weak ( C , D ), moderate ( E , F ) and strong expression ( G , H ) of SPP1. Images were taken using 10× and 40× magnification objectives (scale bar equals 1 mm).

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Cytoplasmic expression of SPP1 in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( A , B ), weak ( C , D ), moderate ( E , F ) and strong expression ( G , H ) of SPP1. Images were taken using 10× and 40× magnification objectives (scale bar equals 1 mm).

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Immunohistochemical staining, Staining, Microarray

    Nuclear SPP1 expression in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( C , D ), and strong expression of SPP1 ( A , B ). Images were taken with 10× and 40× magnification objectives (scale bar equals 1 mm).

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Nuclear SPP1 expression in bladder carcinoma. Immunohistochemical staining of the bladder cancer tissue microarray using an SPP1 antibody. Figures showing: no expression ( C , D ), and strong expression of SPP1 ( A , B ). Images were taken with 10× and 40× magnification objectives (scale bar equals 1 mm).

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Immunohistochemical staining, Staining, Microarray

    Correlation between cytoplasmic SPP1 expression and patients’ clinicopathological characteristics.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Correlation between cytoplasmic SPP1 expression and patients’ clinicopathological characteristics.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing

    SPP1 expression and patients’ survival. Kaplan–Meier survival curve for bladder cancer patients expressing cytoplasmic ( A ) and nuclear ( B ) patterns of SPP1 (low expression vs. high expression). Low SPP1 immunostaining is associated with poor overall survival (log-rank p = 0.022).

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: SPP1 expression and patients’ survival. Kaplan–Meier survival curve for bladder cancer patients expressing cytoplasmic ( A ) and nuclear ( B ) patterns of SPP1 (low expression vs. high expression). Low SPP1 immunostaining is associated with poor overall survival (log-rank p = 0.022).

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Immunostaining

    Enrichment analysis of SPP1 in bladder cancer. ( A ) Identification of SPP1-interacting genes. Protein–protein interaction map and hub genes of SPP1. The size of the hub is proportional to the expression level. ( B ) Identification of the SPP1 co-expression network. The figure was generated using the online cBioPortal database. ( C ) KEGG functional enrichment analysis of SPP1. The figure was generated using the online cBioPortal database.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Enrichment analysis of SPP1 in bladder cancer. ( A ) Identification of SPP1-interacting genes. Protein–protein interaction map and hub genes of SPP1. The size of the hub is proportional to the expression level. ( B ) Identification of the SPP1 co-expression network. The figure was generated using the online cBioPortal database. ( C ) KEGG functional enrichment analysis of SPP1. The figure was generated using the online cBioPortal database.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing, Generated, Functional Assay

    Correlation between immune cells and SPP1 expression. TIMER analysis of the correlation between SPP1 expression and immune cells’ infiltration. Purity-adjusted Spearman’s rho across various cell types by different algorithms.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Correlation between immune cells and SPP1 expression. TIMER analysis of the correlation between SPP1 expression and immune cells’ infiltration. Purity-adjusted Spearman’s rho across various cell types by different algorithms.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing

    Relationship between SPP1 expression and immune checkpoint genes in bladder cancer. ( A ) Correlation analysis between SPP1 expression and immune checkpoint genes. ( B ) The expression of immune checkpoint genes in relation to SPP1 expression. Data were analyzed using the cBioPortal cancer genomics website on TCGA data. The p -value significance codes: *** ≤0.001, ** ≤0.01, * ≤0.05.

    Journal: Cancers

    Article Title: Identification of SPP1 as a Prognostic Biomarker and Immune Cells Modulator in Urothelial Bladder Cancer: A Bioinformatics Analysis

    doi: 10.3390/cancers15235704

    Figure Lengend Snippet: Relationship between SPP1 expression and immune checkpoint genes in bladder cancer. ( A ) Correlation analysis between SPP1 expression and immune checkpoint genes. ( B ) The expression of immune checkpoint genes in relation to SPP1 expression. Data were analyzed using the cBioPortal cancer genomics website on TCGA data. The p -value significance codes: *** ≤0.001, ** ≤0.01, * ≤0.05.

    Article Snippet: The slides were then incubated with the primary polyclonal human anti-SPP1 antibody (Spring Bioscience, Pleasanton, CA, USA. cat#E3284) at a dilution of 1:100 for 32 min.

    Techniques: Expressing